Aller au contenu principal
Profil bibliographique

Moses Chitsamatanga

Informations fournies par OpenAlex. Research Africa ne déduit ni nationalité, ni poste, ni coordonnées personnelles.

3Publications signalées
3Citations signalées
1Affiliations récentes

Les institutions déclarées

Les domaines associés

HIV/AIDS drug development and treatmentHIV/AIDS Research and InterventionsVirus-based gene therapy researchPneumonia and Respiratory InfectionsAntibiotic Use and Resistance

Les publications récentes

Accès ouvert 2026 article OpenAlex

Switch to injectable cabotegravir–rilpivirine given every 8 weeks in adolescents living with HIV with virological suppression in sub-Saharan Africa (LATA): a randomised, open-label, multicentre, 96-week non-inferiority trial

Mutsa Bwakura-Dangarembizi, Elizabeth Chappell, Cissy Kityo, Diana Louis Anena et autres

BACKGROUND: Adolescents living with HIV have poorer treatment outcomes than other age groups and might benefit from long-acting-injectable (LAI) antiretroviral therapy (ART). We evaluated efficacy and safety of LAI cabotegravir-rilpivirine compared with daily oral ART in adolescents living with HIV with virological …

Zimbabwe, gb, Ouganda, Kenya, Afrique du Sud, it, nl (code pays fourni par la source)

0 citations The Lancet
Accès ouvert 2026 article OpenAlex

Oral step-down, optimal drug, and total duration of antibiotic treatment in African children hospitalised with severe community-acquired pneumonia (PediCAP): a factorial randomised controlled trial

Julia Anna Bielicki, Michelle Clements, Victor Musiime, David Paul Moore et autres

BACKGROUND: WHO recommends 5 days of intravenous antibiotics for children hospitalised with severe community-acquired pneumonia (CAP). We aimed to investigate the safety of a step-down to different oral antibiotics and the shortest effective duration. METHODS: PediCAP was an open-label, parallel group, 2 …

gb, Ouganda, Afrique du Sud, Mozambique, Zambie, Zimbabwe, it (code pays fourni par la source)

3 citations The Lancet
Accès ouvert 2026 article OpenAlex

Empirical treatment with valganciclovir in infants living with HIV and hospitalised with severe pneumonia in Africa: a multicentre, open-label, factorial, randomised, controlled, superiority trial

Cinta Moraleda, Alfredo Tagarro, Sara Domínguez‐Rodríguez, Victor Musiime et autres

BACKGROUND: Mortality among infants with severe HIV-associated pneumonia remains high. This trial (EMPIRICAL) tested whether empirical valganciclovir treatment for cytomegalovirus improves survival in infants in Africa. METHODS: This multicentre, open-label, group-sequential designed, 2 × 2 factorial, randomised, controlled, superiority trial was conducted …

es, Ouganda, Zimbabwe, Zambie, Malawi, gb, Mozambique, Côte d’Ivoire, fr, nl, it, cu (code pays fourni par la source)

0 citations The Lancet

BNTIC News n’est pas le producteur de ces données. Les publications sont interrogées à la demande dans Crossref, OpenAIRE, DOAJ, Europe PMC, HAL, DataCite, AfricArXiv, ROR et la Banque mondiale, sans clé d’accès. OpenAlex reste optionnel. Aucun service payant n’est nécessaire et aucune donnée externe n’est enregistrée en base. Consulter les sources et leurs limites.